The Effects of Mesenchymal Stem Cell Secretome in Lupus Patients
NCT ID: NCT05921058
Last Updated: 2023-06-27
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1/PHASE2
15 participants
INTERVENTIONAL
2022-08-01
2023-03-09
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Human Umbilical Cord Mesenchymal Stem Cells Treatment for Lupus Nephritis (LN)
NCT03580291
Effect of Mesenchymal Stem Cell Transplantation for Lupus Nephritis
NCT00659217
Pilot Trial of Mesenchymal Stem Cells for Systemic Lupus Erythematosus
NCT03171194
Umbilical Cord Derived Mesenchymal Stem Cells Therapy in Systemic Lupus Erythematosus
NCT03219801
Treatment of Systemic Lupus Erythematosus With Pooled Allogenic Mesenchymal Stem Cells
NCT04184258
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Messenchymal stem cell secretome
The hypoxic mesenchymal stem cell secretome has been developed up to chapter 7, stored at -196 C to -135 C in cryopreservation, and has passed quality tests.
Secretome
Mesenchymal stem cell secretome obtained from Kalbe Pharma Company
Placebo
Nacl 0,9% infusion
Placebo
NaCl 0,9% infusion
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Secretome
Mesenchymal stem cell secretome obtained from Kalbe Pharma Company
Placebo
NaCl 0,9% infusion
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Years
60 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Universitas Sebelas Maret
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Arief Nurudhin
MD. Ph.D
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Nurhasan Agung Prabowo, MD
Role: PRINCIPAL_INVESTIGATOR
Universitas Sebelas Maret
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Moewardi General Hospital
Surakarta, Middle Java, Indonesia
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Pratama YS, Pradiptakirana R, Rachmah A, Prabowo NA. Autoimmune Thrombocytopenia in SLE and COVID-19. Eur J Case Rep Intern Med. 2021 Nov 3;8(11):002863. doi: 10.12890/2021_002863. eCollection 2021.
Sholihah MM, Kusuma TRH, Hanif MI, Prabowo NA. Letter to the Editor on Type 1 diabetes onset triggered by COVID-19. Acta Diabetol. 2021 Sep;58(9):1283-1284. doi: 10.1007/s00592-021-01761-3. Epub 2021 Jun 28. No abstract available.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NAP05
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.